Skip to main content

Table 1

From: Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data

 

Wk 12

Wk 52

 

Control

TCZ

TCZ

JIA ACR responses, n (%)

(N=37)

(N=75)

(N=88)

ACR30 = absence of fever

9 (24)

64 (85)

77 (88)

ACR70

3 (8)

53 (71)

78 (89)

ACR90

2 (5)

28 (37)

57 (65)

Back to article page

Pediatric Rheumatology

ISSN: 1546-0096